A 28-year-old woman with opioid use disorder presents to a de-addiction centre for treatment initiation. Regarding the clinical management and pharmacotherapy of opioid use disorder, all of the following statements are correct EXCEPT:

Explanation

## Pharmacotherapy of Opioid Use Disorder ### Maintenance Therapies **High-Yield:** The three FDA-approved medications for opioid use disorder maintenance are methadone, buprenorphine, and naltrexone. Each has distinct pharmacology and clinical indications. #### Buprenorphine **Key Point:** Buprenorphine is a **partial mu-opioid agonist** with a "ceiling effect" on respiratory depression, making it significantly safer in overdose than full agonists. - Lower overdose mortality risk compared to methadone - Can be initiated in office-based settings - Produces milder withdrawal syndrome - Longer half-life (24–72 hours) allows less frequent dosing #### Naltrexone **Key Point:** Naltrexone is a **pure opioid antagonist** that blocks all opioid effects. It requires complete detoxification before initiation to avoid precipitated withdrawal. - Used for maintenance therapy in motivated patients - Prevents relapse by blocking euphoria from opioid use - Extended-release formulation (Vivitrol) available for monthly dosing - Requires 7–10 days of abstinence before initiation ### Withdrawal Management **Clinical Pearl:** Clonidine and lofexidine are alpha-2 adrenergic agonists used to manage acute withdrawal symptoms by suppressing noradrenergic hyperactivity. | Agent | Mechanism | Advantages | Disadvantages | |-------|-----------|-----------|---------------| | Clonidine | Alpha-2 agonist | Reduces autonomic symptoms | Hypotension, sedation, rebound hypertension | | Lofexidine | Alpha-2 agonist (selective) | More selective; less hypotension | Similar efficacy to clonidine; not superior | | Buprenorphine | Partial mu-agonist | Reduces withdrawal; therapeutic | Requires monitoring; potential for misuse | ### Key Distinction: Clonidine vs. Lofexidine **Warning:** A common misconception is that lofexidine is "superior" to clonidine. While lofexidine has greater selectivity for alpha-2A receptors and causes less hypotension, **clinical efficacy in managing opioid withdrawal is comparable**. Lofexidine is not superior; it is an alternative with a better side-effect profile. **Mnemonic:** **CLAN** = **CL**onidine and **AN**tidepressants manage withdrawal (clonidine for autonomic; antidepressants for mood). ### Correct Answer Rationale Option 4 (lofexidine is superior to clonidine) is **incorrect**. While lofexidine has greater alpha-2A selectivity and causes less hypotension, the two agents have **comparable clinical efficacy** in managing opioid withdrawal. Lofexidine is an alternative option with a better tolerability profile, not a superior agent.